Baruch Kuppermann discusses the challenges of treating patients with dry AMD. Unlike wet AMD, which is responsive to anti-VEGF therapy, there are multiple challenges with wet AMD including the complement pathway and neuroprotection. There is an ongoing search into new ways of tracking wet AMD to find appropriate endpoints for clinical trials.
KEYWORDS: wet AMD, age-related macular degeneration, complement pathway, drusen, geographic atrophy, clinical trials, neuroprotection, autoflorescence, efficacy end-points, microperimetry
